LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Home・Aandelen Lijst・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Gesloten

SectorGezondheidszorg

37.02 2.89

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

36.12

Max

37.05

Belangrijke statistieken
By Trading Economics
Inkomsten	11M 51M
Verkoop	39M 239M
K/W Sectorgemiddelde	11.202 79.874
EPS	1.08
Winstmarge	21.242
Werknemers	268
EBITDA	14M 73M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+29.54% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	358M 2B
Vorige openingsprijs	34.13
Vorige sluitingsprijs	37.02

Nieuwssentiment

By Acuity

44%

56%

145 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

29.8 / N/A Steun & Weerstand

Harmony Biosciences Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 dec 2025, 17:29 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2 dec 2025, 16:21 UTC

Winsten

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2 dec 2025, 16:18 UTC

Winsten

Correction to Scotiabank Quarterly Earnings Buoyed Article

2 dec 2025, 23:53 UTC

Marktinformatie

Nikkei May Rise After Gains on Wall Street -- Market Talk

2 dec 2025, 22:48 UTC

Winsten

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2 dec 2025, 22:12 UTC

Marktinformatie

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2 dec 2025, 22:03 UTC

Marktinformatie

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2 dec 2025, 22:00 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 dec 2025, 22:00 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

2 dec 2025, 22:00 UTC

Marktinformatie

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2 dec 2025, 21:56 UTC

Winsten

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dec 2025, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

2 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

2 dec 2025, 21:44 UTC

Winsten

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dec 2025, 21:38 UTC

Marktinformatie

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2 dec 2025, 21:19 UTC

Winsten

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dec 2025, 20:06 UTC

Marktinformatie

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2 dec 2025, 19:55 UTC

Marktinformatie

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2 dec 2025, 19:53 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

2 dec 2025, 19:53 UTC

Marktinformatie

Winsten

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2 dec 2025, 19:24 UTC

Marktinformatie

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2 dec 2025, 19:06 UTC

Marktinformatie

Precious Metals Step Back After Silver Sets Record -- Market Talk

2 dec 2025, 18:27 UTC

Acquisities, Fusies, Overnames

Kraken to Acquire Backed Finance AG

2 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 dec 2025, 17:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

2 dec 2025, 15:17 UTC

Marktinformatie

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2 dec 2025, 14:47 UTC

Marktinformatie

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2 dec 2025, 14:38 UTC

Marktinformatie

Silver Steps Back From Record Levels -- Market Talk

2 dec 2025, 14:31 UTC

Marktinformatie

Winsten

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Peer Vergelijking

Prijswijziging

Harmony Biosciences Holdings Inc Prognose

Koersdoel

By TipRanks

29.54% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 46 USD 29.54%

Hoogste 62 USD

Laagste 32 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harmony Biosciences Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Harmony Biosciences Holdings Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

29.8 / N/ASteun & Weerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

145 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.